组蛋白修饰在系统性红斑狼疮发病机制中作用的研究进展

doi:10.20047/j.issn1673-7210.2023.30.13

Abstract
Figure/Table
References
Related Citation (15)

Download: PDF (475 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract The occurrence and development of systemic lupus erythematosus（SLE） are regulated by epigenetic mechanisms, and histone modifications also play an important role in disease progression. SLE patients exhibit changes in histone modification patterns of autoreactive T cells and B cells, including methylation (CREMα, CXCR5, HPK1, EZH2, TNFAIP3, BACH2, etc.), acetylation (BCL-6, BACH2, IL-2/10/17, etc.), phosphorylation, ubiquitination, etc. And these changes may be caused by changes in the level of specific histone modifying enzymes, while the role of histone modifying enzymes and changes in histone modifying levels in SLE is currently in the exploratory stage. This article provides a brief overview of the research progress of histone modification in SLE, and introduces therapeutic drugs targeting epigenetic targets.

Key words： Systemic lupus erythematosus Autoimmune diseases Epigenetics Histone modification

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	MIAO Lin WANG Qingcui CHEN Xiaohua

Cite this article:

MIAO Lin WANG Qingcui CHEN Xiaohua. Research progress on the role of histone modification in the pathogenesis of systemic lupus erythematosus[J]. 中国医药导报, 2023, 20(30): 68-71.

URL:

https://www.yiyaodaobao.com.cn/EN/10.20047/j.issn1673-7210.2023.30.13 OR https://www.yiyaodaobao.com.cn/EN/Y2023/V20/I30/68

[1] Li M，Zhao Y，Zhang Z，et al. 2020 Chinese Guidelines for the diagnosis and treatment of systemic lupus erythematosus [J]. Rheumatol Immunol Res，2020，1（1）：5-23.
[2] Kiriakidou M，Ching CL. Systemic lupus erythematosus [J]. Ann Intern Med，2020，172（11）：Itc81-Itc96.
[3] Gibson F，Hanly A，Grbic N，et al. Epigenetic dysregulation in autoimmune and inflammatory skin diseases [J]. Clin Rev Allergy Immunol，2022，63（3）：447-471.
[4] Hu N，Qiu X，Luo Y，et al. Abnormal histone modification patterns in lupus CD4+ T cells [J]. J Rheumatol，2008，35（5）：804-810.
[5] Luo S，Zhang H，Xie Y，et al. Decreased SUV39H1 at the promoter region leads to increased CREMα and accelerates autoimmune response in CD4+ T cells from patients with systemic lupus erythematosus [J]. Clin Epigenetics，2022，14（1）： 181.
[6] Liao J，Luo S，Yang M，et al. Overexpression of CXCR5 in CD4+ T cells of SLE patients caused by excessive SETD3 [J]. Clin Immunol，2020，214：108406.
[7] Zhang Q，Long H，Liao J，et al. Inhibited expression of hematopoietic progenitor kinase 1 associated with loss of jumonji domain containing 3 promoter binding contributes to autoimmunity in systemic lupus erythematosus [J]. J Autoimmun，2011，37（3）：180-189.
[8] Wu L，Jiang X，Qi C，et al. EZH2 inhibition interferes with the activation of type Ⅰ interferon signaling pathway and ameliorates lupus nephritis in NZB/NZW F1 mice [J]. Front Immunol，2021，12：653989.
[9] Zhen Y，Smith RD，Finkelman FD，et al. Ezh2-mediated epigenetic modification is required for allogeneic T cell-induced lupus disease [J]. Arthritis Res Ther，2020，22（1）：133.
[10] Katsuyama E，Suarez-Fueyo A，Bradley SJ，et al. The CD38/ NAD/SIRTUIN1/EZH2 axis mitigates cytotoxic CD8 T cell function and identifies patients with SLE prone to infections [J]. Cell Rep，2020，30（1）：112.e114-123.e114.
[11] Zhang Q，Liu Y，Liao J，et al. Deficiency of p53 causes the inadequate expression of miR-1246 in B cells of systemic lupus erythematosus [J]. J Immunol，2022，209（8）：1492- 1498.
[12] Zhang M，Iwata S，Hajime M，et al. Methionine commits cells to differentiate into plasmablasts through epigenetic regulation of BTB and CNC homolog 2 by the methyltransferase EZH2 [J]. Arthritis Rheumatol，2020，72（7）：1143-1153.
[13] Gautam P，Sharma A，Bhatnagar A. Global histone modification analysis reveals hypoacetylated H3 and H4 histones in B Cells from systemic lupus erythematosus patients [J]. Immunol Lett，2021，240：41-45.
[14] Wang Z，Zhao M，Yin J，et al. E4BP4-mediated inhibition of T follicular helper cell differentiation is compromised in autoimmune diseases [J]. J Clin Invest，2020，130（7）：3717- 3733.
[15] Hisada R，Yoshida N，Umeda M，et al. The deacetylase SIRT2 contributes to autoimmune disease pathogenesis by modulating IL-17A and IL-2 transcription [J]. Cell Mol Immunol，2022，19（6）：738-750.
[16] Liu L，Hu L，Long H，et al. LncRNA IL21-AS1 interacts with hnRNPU protein to promote IL21 overexpression and aberrant differentiation of Tfh cells in systemic lupus erythematosus [J]. Clin Transl Med，2022，12（12）：e1117.
[17] Apostolidis SA，Rauen T，Hedrich CM，et al. Protein phosphatase 2A enables expression of interleukin 17 （IL-17） through chromatin remodeling [J]. J Biol Chem，2013，288（37）：26775-26784.
[18] Hedrich CM，Crispin JC，Rauen T，et al. cAMP response element modulator α controls IL2 and IL17A expression during CD4 lineage commitment and subset distribution in lupus [J]. Proc Natl Acad Sci U S A，2012，109（41）：16606- 16611.
[19] Zheng Y，Lu Y，Huang X，et al. BACH2 regulates the function of human CD4+CD45RA-Foxp3lo cytokine-secreting T cells and promotes B-cell response in systemic lupus erythematosus [J]. Eur J Immunol，2020，50（3）：426-438.
[20] Namas R，Renauer P，Ognenovski M，et al. Histone H2AX phosphorylation as a measure of DNA double-strand breaks and a marker of environmental stress and disease activity in lupus [J]. Lupus Sci Med，2016，3（1）：e000148.
[21] Armache A，Yang S，Martínez De Paz A，et al. Histone H3.3 phosphorylation amplifies stimulation-induced transcription [J]. Nature，2020，583（7818）：852-857.
[22] Martire S，Gogate AA，Whitmill A，et al. Phosphorylation of histone H3.3 at serine 31 promotes p300 activity and enhancer acetylation [J]. Nat Genet，2019，51（6）：941-946.
[23] Liu L，Hu L，Yang L，et al. UHRF1 downregulation promotes T follicular helper cell differentiation by increasing BCL6 expression in SLE [J]. Clin Epigenetics，2021，13（1）：31.
[24] Wang X，Yang J，Han L，et al. TRAF5-mediated lys-63- linked polyubiquitination plays an essential role in positive regulation of RORγt in promoting IL-17A expression [J]. J Biol Chem，2015，290（48）：29086-29094.
[25] Kumar R，Theiss AL，Venuprasad K. RORγt protein modifications and IL-17-mediated inflammation [J]. Trends Immunol，2021，42（11）：1037-1050.
[26] Zhang F，Zhang B，Tang R，et al. The occurrence of lupus nephritis is regulated by USP7-mediated JMJD3 stabilization [J]. Immunol Lett，2021，235：41-50.
[27] Liu D，Zhao Z，She Y，et al. TRIM14 inhibits OPTN-mediated autophagic degradation of KDM4D to epigenetically regulate inflammation [J]. Proc Natl Acad Sci U S A，2022， 119（7）：e2113454119.
[28] Fanouriakis A，Kostopoulou M，Cheema K，et al. 2019 Update of the Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association （EULAR/ERA-EDTA） recommendations for the management of lupus nephritis [J]. Ann Rheum Dis，2020，79（6）：713-723.
[29] Salvi V，Bosisio D，Mitola S，et al. Trichostatin A blocks type Ⅰ interferon production by activated plasmacytoid den- dritic cells [J]. Immunobiology，2010，215（9/10）：756-761.
[30] Shu J，Li L，Zhou L B，et al. IRF5 is elevated in childhood- onset SLE and regulated by histone acetyltransferase and histone deacetylase inhibitors [J]. Oncotarget，2017，8（29）：47184-47194.
[31] Zhao M，Sun Y，Gao F，et al. Epigenetics and SLE：RFX1 downregulation causes CD11a and CD70 overexpression by altering epigenetic modifications in lupus CD4+ T cells [J]. J Autoimmun，2010，35（1）：58-69.
[32] Sung WY，Lin YZ，Hwang DY，et al. Methylation of TET2 promoter is associated with global hypomethylation and hypohydroxymethylation in peripheral blood mononuclear cells of systemic lupus erythematosus patients [J]. Diagnostics（Basel），2022，12（12）：3006.
[33] Tanaka S，Ise W，Inoue T，et al. Tet2 and Tet3 in B cells are required to repress CD86 and prevent autoimmunity [J]. Nat Immunol，2020，21（8）：950-961.
[34] Nikolova-Ganeva K，Bradyanova S，Manoylov I，et al. Methyl- rich diet ameliorates lupus-like disease in MRL/lpr mice [J]. Immunobiology，2022，227（6）：152282.